---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-088481"
form_type: "8-K"
ticker: "ELUT"
cik: "0001708527"
company_name: "ELUTIA INC."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:19:32.028333+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Elutia sells CIED business to Boston Scientific for up to $88M; funds breast reconstruction pipeline

## Summary
- Asset sale of EluPro/CanGaroo bioenvelope business to Boston Scientific (BSX) for $80M at closing plus $8M escrow.
- Proceeds to eliminate outstanding debt, resolve Orthobiologics litigation, and fund NXT-41 advancement without dilution.
- Transaction expected to close in Q4 2025, subject to customary closing conditions.
- Elutia to focus resources on SimpliDerm franchise and drug-eluting pipeline in the $1.5B US breast reconstruction market.
- BofA Securities served as financial advisor to Elutia on the sale.

## SEC filing metadata
- accession: 0001104659-25-088481
- form_type: 8-K
- ticker: ELUT
- cik: 0001708527
- company_name: ELUTIA INC.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708527/000110465925088481/0001104659-25-088481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708527/000110465925088481/tm2525591d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-088481
- JSON: https://secwatch.observer/filing/0001104659-25-088481.json
- Plain text: https://secwatch.observer/filing/0001104659-25-088481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.